natgillin/translations-raw huggingface dataset:
Some side effects observed with adalimumab may not have symptoms and may only be discovered through 
Nekateri neželeni učinki, opaženi pri adalimumabu, nimajo simptomov in se jih lahko odkrije le pri
8) Before injecting, read steps A-C to learn correct way to administer dose. 
8) Pred injiciranjem preberite točke od A do C, da boste spoznali pravilen način za dovajanje odmerka
Efficacy of adalimumab for the treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and drug effects are substantially similar to that of adults at the same exposure levels. 
Učinkovitost adalimumaba za zdravljenje mladostnikov s HS je napovedana na podlagi dokazane učinkovitosti in razmerja med izpostavljenostjo in odzivom pri odraslih bolnikih s HS ter verjetnosti, da so potek bolezni, patofiziologija in učinek zdravila bistveno podobni kot pri odraslih bolnikih, pri enaki ravni izpostavljenosti.
Percent of patients achieving PASI75 response was calculated as centre-adjusted rate 
Odstotek bolnikov, ki so dosegli odziv PASI 75, je bil izračunan kot delež, korigiran za center.
• Cyltezo should only be used during a pregnancy if needed. 
• Zdravilo Cyltezo se med nosečnostjo lahko uporablja samo, če je potrebno.
These infections may be serious and include tuberculosis, infections caused by viruses, fungi, parasites or bacteria, other opportunistic infections (unusual infections associated with a weakened immune system) and sepsis (blood poisoning). 
Te okužbe so lahko resne in vključujejo tuberkulozo, okužbe, ki jih povzročijo virusi, glive, paraziti ali bakterije, druge oportunistične okužbe (nenavadne okužbe, povezane z oslabljenim imunskim sistemom) in sepso (zastrupitev krvi).
Ophthalmologists are advised to consult with an appropriate specialist before initiation of treatment with Cyltezo (see section 4.4). 
Oftalmologom se svetuje, da se pred začetkom zdravljenja z zdravilom Cyltezo posvetujejo z ustreznim specialistom (glejte poglavje 4.4).
During the withdrawal period, symptoms of psoriasis returned over time with a median time to relapse (decline to PGA “moderate” or worse) of approximately 5 months. 
Med obdobjem prenehanja uporabe so se simptomi psoriaze sčasoma znova pojavili; mediana časa do ponovitve simptomov psoriaze (relapsa) (poslabšanje na PGA "zmerno" ali slabše) je bil približno 5 mesecev.
Among those, 109 subjects (63.7 %) were reported to be in remission at 10 years. 
Med temi je bilo 109 oseb (63,7 %) po 10 letih v
After adjustment for weight differences, gender and age appeared to have a minimal effect on adalimumab clearance. 
Po korekciji za razlike v telesni masi se je izkazalo, da spol in starost po vsem sodeč minimalno vplivata na očistek adalimumaba.
Then take your next dose as you would have on your originally scheduled day, had you not 
Nato uporabite naslednji odmerek, kot bi ga uporabili po prvotnem urniku injiciranja, če ne bi pozabili
The benefits and risks of continued 40 mg weekly or 80 mg every other week therapy should be carefully reconsidered in a patient with an inadequate response after the increase in dosage (see section 5.1). 
Koristi in tveganja nadaljevanja zdravljenja s 40 mg vsak teden ali 80 mg vsak drugi teden je treba ponovno natančno pretehtati pri bolniku z nezadostnim odzivom na zdravljenje po povečanju odmerka (glejte poglavje 5.1).
Concomitant corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating treatment with Cyltezo. 
Kortikosteroide, ki se jih daje sočasno, se lahko postopoma ukinja v skladu s klinično prakso, z začetkom dva tedna po začetku zdravljenja z zdravilom Cyltezo.
The MAH shall ensure that in each Member State where Cyltezo is marketed, all healthcare professionals who are expected to prescribe Cyltezo have are provided with the following educational package: 
Imetnik dovoljenja za promet z zdravilom mora v vsaki državi članici, kjer se zdravilo Cyltezo trži, zagotoviti, da bodo vsi zdravstveni delavci, ki bodo zdravilo Cyltezo predpisovali, prejeli izobraževalno gradivo, ki ga sestavljata:
Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis are inflammatory diseases of the joints that usually first appear in childhood. 
Poliartikularni juvenilni idiopatski artritis in artritis, povezan z entezitisom sta vnetni bolezni sklepov, ki se običajno najprej pojavi v otroštvu.
Patients on Cyltezo may receive concurrent vaccinations, except for live vaccines. 
Bolniki, ki prejemajo zdravilo Cyltezo, lahko sočasno dobijo cepiva, razen živih cepiv.
• Do not select tender, bruised, or scarred areas. 
• Ne izberite občutljivega, poškodovanega ali brazgotinastega predela.
In CD Study III, at week 4, 58 % (499/854) of patients were in clinical response and were assessed in the primary analysis. 
V študiji pri Crohnovi bolezni III je imelo 4. teden klinični odziv 58 % (499/854) bolnikov; ti so bili ocenjeni v primarni analizi.
40 mg every other week in combination with methotrexate - Not applicable. 
40 mg vsak drugi teden v kombinaciji z metotreksatom - Navedba smiselno ni potrebna.
Adalimumab is used to treat Crohn's disease in adults and children aged 6 to 17 years. 
Adalimumab se uporablja za zdravljenje Crohnove bolezni pri odraslih in otrocih, starih 6 do 17 let.
• You should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 5 months after the last Cyltezo treatment. 
• Premisliti morate o uporabi ustrezne kontracepcijske zaščite za preprečitev nosečnosti in z njo nadaljevati vsaj še 5 mesecev po zadnjem zdravljenju z zdravilom Cyltezo.
o Press injection button once (you should hear a ‘click' that indicates the start of injection) and keep pen pressed firmly against skin while you slowly count to 10. 
Gumb za injiicranje se bo odklenil in bo o Enkrat pritisnite gumb za injiciranje (zaslišali boste "klik", ki predstavlja začetek injiciranja) in peresnik držite močno pritisnjen na kožo, medtem ko počasi štejete do 10. o Med injiciranjem peresnika ne premikajte.
The proportions of subjects with PedACR50/70/90 at week 12 and week 24 were 90.3 %/61.3 %/38.7 % and 83.3 %/73.3 %/36.7 %, respectively. 
Deleži preiskovancev s PedACR50/70/90 so bili 12. teden 90,3 %/61,3 %/38,7 % in 24. teden 83,3 %/73,3 %/36,7 %.
Gather supplies onto clean, flat surface: a. 
Pripomočke zberite na čisti, ravni površini:
At week 16, a statistically significantly greater proportion of patients who received adalimumab achieved PGA of 'clear' or 'almost clear' for the hands and/or feet compared to patients who received placebo (30.6 % versus 4.3 %, respectively [p = 0.014]). 
V 16. tednu je statistično pomembno večji delež bolnikov, ki so prejemali adalimumab, doseglo PGA "čisto" ali "skoraj čisto" za dlani in/ali stopala, v primerjavi z bolniki, ki so prejemali placebo (30,6 % proti 4,3 %, v tem zaporedju [P = 0,014]).
• immune disorders that could affect the lungs, skin and lymph nodes (most commonly as a condition 
• imunske bolezni, ki lahko prizadenejo pljuča, kožo in limfne vozle (najpogosteje kot stanje,
The frequency of serious infections among adalimumab treated subjects over 65 years of age (3.7 %) was higher than for those under 65 years of age (1.5 %). 
Pogostost resnih okužb je bila pri bolnikih starejših od 65 let, ki so prejemali adalimumab, večja (3,7 %) kot pri bolnikih mlajših od 65 let (1,5 %).
Week 26 Placebo-Controlled 
26. teden Kontrolirana s placebom
Thus, it is not possible to administer Cyltezo to paediatric patients that require less than a full 40 mg dose. 
Zato zdravila Cyltezo ni mogoče dajati pediatričnim bolnikom, ki potrebujejo odmerek, nižji od 40 mg.
Placebo/MTXAdalimumab/MTX (95 % Confidence Interval p-value 
placebo/MTXadalimumab/MTX (95-% interval zaupanja vrednost p
Thus additional caution should be exercised in considering Cyltezo treatment of these patients (see section 4.8). 
Torej je potrebna dodatna previdnost, kadar razmišljamo o zdravljenju z zdravilom Cyltezo pri teh bolnikih (glejte poglavje 4.8).
The active ingredient in Cyltezo, adalimumab, is a monoclonal antibody. 
Učinkovina v zdravilu Cyltezo, adalimumab, je monoklonsko protitelo.
If you take Cyltezo the risk of getting lymphoma, leukaemia, or other cancers may increase. 
Če uporabljate zdravilo Cyltezo, se vam lahko poveča tveganje za pojav limfoma, levkemije ali drugih vrst raka.
Cyltezo treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which Cyltezo is indicated. 
Zdravljenje z zdravilom Cyltezo mora uvesti in nadzorovati zdravnik specialist, izkušen v diagnosticiranju in zdravljenju bolezni, za katere je zdravilo Cyltezo indicirano.
Treatment with Cyltezo should not be initiated in patients with active infections including chronic or localised infections until infections are controlled. 
Zdravljenja z zdravilom Cyltezo se ne sme začeti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi, dokler te niso obvladane.
This evaluation should include colonoscopy and biopsies per 
Takšna ocena mora vključevati kolonoskopijo in biopsije v skladu z lokalnimi priporočili.
• Hold pen straight up from injection site (at a 90 degree angle). 
• Peresnik držite pravokotno na mesto injiciranja (pod kotom 90 stopinj).
• autoimmune hepatitis (inflammation of the liver caused by the body's own immune system); 
• avtoimuni hepatitis (vnetje jeter, ki ga povzroči lastni imunski sistem);
• oedema (a build up of fluid in the body which causes the affected tissue to swell); • reduction in blood platelets which increases risk of bleeding or bruising; 
• edem (nakopičenje tekočine v telesu, ki povzroči oteklino prizadetega tkiva); • zmanjšanje števila krvnih ploščic, kar poveča tveganje krvavitev ali podplutb;
• If you receive Cyltezo during your pregnancy, your baby may have a higher risk for getting an 
• Če prejmete zdravilo Cyltezo med nosečnostjo, obstaja večje tveganje, da bo vaš dojenček
Each pack contains 1, 2, 4 or 6 pre-filled syringes for patient use with 2, 2, 4 or 6 alcohol pads, respectively. 
Eno pakiranje vsebuje 1, 2, 4 oz. 6 napolnjenih injekcijskih brizg za bolnikovo uporabo z 2, 2, 4 oz. 6 alkoholnimi zloženci.
RA studies III and V had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by X-ray results). 
V študijah III in V je bil dodaten primarni opazovani dogodek po 52 tednih upočasnitev napredovanja bolezni (ugotovljena z izvidi rentgenskega slikanja).
Ps Study IV Efficacy Results at 16, 26 and 52 Weeks 
Preglednica 19: Študija pri psoriazi IV - rezultati učinkovitosti po 16, 26 in 52 tednih
Adalimumab was numerically favoured for the majority of subscores with statistically significant mean differences for general vision, ocular pain, near vision, mental health, and total score in Study UV I, and for general vision and mental health in Study UV II. 
Številke so bile v korist adalimumaba za večino podocen s statistično značilno povprečno razliko za splošni vid, očesno bolečino, vid na blizu, duševno zdravje in skupen rezultat v študiji UV I, ter za splošni vid in duševno zdravje v študiji UV II.
In general, the adverse events in paediatric patients were similar in frequency and type to those seen in adult 
Na splošno so bili neželeni učinki pri pediatričnih bolnikih po pogostnosti in vrsti podobni neželenim učinkom, opaženih pri odraslih bolnikih.
At week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically relevant decrease in HS-related skin pain (see Table 21). 
V 12. tednu je statistično pomembno večji delež bolnikov v študiji HS-II občutil klinično pomembno zmanjšanje bolečine na koži, povezane s HS (glejte preglednico 21).
• Always keep “sharps” container out of sight and reach of children. 
• Vsebnik za ostre predmete vedno hranite zunaj dosega otrok.
The primary efficacy endpoint was the proportion of patients with no flare by week 68 of the study. 
Primarni opazovani dogodek kot merilo učinkovitosti je bil delež bolnikov brez ponovnega zagona bolezni do 68. tedna študije.
Plunger should reach bottom of syringe. 
Bat mora doseči dno
Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Cyltezo in patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot 
O uporabi protituberkuloznega profilaktičnega zdravljenja morate pred uvedbo zdravila Cyltezo razmisliti tudi pri bolnikih s hudimi ali pomembnimi faktorji tveganja za tuberkulozo kljub negativnemu testu za tuberkulozo in pri bolnikih z anamnezo latentne ali aktivne tuberkuloze, pri katerih ni mogoče potrditi ustreznega zdravljenja.
You should continue to inject Cyltezo for as long as your doctor has told you. 
Nadaljevati morate z injiciranjem zdravila Cyltezo tako dolgo, kot vam je naročil zdravnik.
It is recommended that children, if possible, be given all the scheduled vaccinations for their age before they start treatment with Cyltezo. 
Za otroke je priporočljivo, da dobijo vsa cepiva, načrtovana za njihovo starost, pred začetkom zdravljenja z zdravilom Cyltezo, če je le mogoče.
The expiry date refers to the last day of that month. 
Rok uporabnosti zdravila se izteče na zadnji dan
Among the 250 subjects who completed the open-label extension study, improvements in physical function were maintained through 10 years of treatment. 
Med 250 osebami, ki so zaključile podaljšano odprto študijo, se je izboljšanje telesne funkcije ohranilo
People with more serious rheumatoid arthritis who have had the disease for a long time may have a higher than average risk of getting lymphoma (a cancer that affects the lymph system), and leukaemia (a cancer that affects the blood and bone marrow). 
Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen že dolgo, obstaja povečana verjetnost, da zbolijo za limfomom (rakom, ki prizadene limfatični sistem) in levkemijo (rak, ki prizadene kri in kostni mozeg).
Note: Treatment failure at or after week 6 (Study UV I), or at or after week 2 (Study UV II), was counted as event. 
Opomba: Neuspeh zdravljenja v ali po 6. tednu (študija UV I) ali v ali po 2. tednu (študija UV II) je bil štet kot dogodek.
If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis treatment before the initiation of Cyltezo, and in accordance with local recommendations. 
Če ugotovite latentno tuberkulozo, morate pred uvedbo zdravila Cyltezo začeti s protituberkuloznim profilaktičnim zdravljenjem v skladu z lokalnimi priporočili.
They are displayed by system organ class and frequency in Table 6 below: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000); and not known (cannot be estimated from the available data). 
Naslednji seznam neželenih učinkov je osnovan na izkušnjah iz kliničnih preskušanj in iz obdobja trženja zdravila in jih razvršča po organskih sistemih in pogostnosti v preglednici 6 spodaj: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Cyltezo can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 
Zdravilo Cyltezo je mogoče uporabiti kot monoterapijo v primeru intolerance za metotreksat ali kadar nadaljnje zdravljenje z metotreksatom ni primerno.
Should treatment be interrupted, Cyltezo may be re-introduced as appropriate. 
Če je treba zdravljenje prekiniti, je možno zdravljenje z zdravilom Cyltezo znova uvesti, kakor je primerno.
N Failure N (%) 
ODSTOTEK NEUSPEHA ZDRAVLJENJA (%)
If you use more Cyltezo than you should 
Če ste uporabili večji odmerek zdravila Cyltezo, kot bi smeli
If an anaphylactic reaction or other serious allergic reaction occurs, administration of Cyltezo should be discontinued immediately and appropriate therapy initiated. 
Če se pojavi anafilaktična reakcija ali kakšna druga resna alergijska reakcija, je treba uporabo zdravila Cyltezo nemudoma prekiniti in uvesti ustrezno zdravljenje.
Improvement in number of active joints with arthritis was maintained during the OL period through week 156 for the 26 of 31 (84%) patients in the adalimumab group who remained in the study. 
Izboljšanje v številu aktivnih sklepov z artritisom se je ohranilo v obdobju odprtega preskušanja po 156. tednu za 26 od 31 (84 %) bolnikov v skupini bolnikov, ki je prejemala adalimumab, ki so ostali v študiji.
PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, both with a similar apparent EC50 of approximately 4.5 µg/mL (95 % CI 0.4-47.6 and 1.9-10.5, respectively). 
PASI 75 in PGA čisto ali minimalno, sta se povečevali z zvečanjem koncentracije adalimumaba, obe s podobno navidezno EC50, za približno 4,5 μg/ml (95% IZ 0,4-47,6 in 1,9-10,5).
Adalimumabcan be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). 
Adalimumab je mogoče uporabiti kot monoterapijo v primeru intolerance za metotreksat ali kadar nadaljnje zdravljenje z metotreksatom ni primerno (za učinkovitost monoterapije glejte poglavje 5.1).
In non-infectious uveitis, corticosteroids or other medicines that influence the immune system may be continued while using Cyltezo. 
V primeru neinfekcijskega uveitisa se kortikosteroidi ali druga zdravila, ki zavirajo imunski sistem, lahko še nadalje uporabljajo ob uporabi zdravila Cyltezo.
• sensation disorders such as tingling, prickling or numbness; • symptoms of nerve root compression (including low back pain and leg pain); 
• motnje v občutenju kot so ščemenje, zbadanje ali omrtvelost; • simptomi stisnenja živčnih korenin (vključno z bolečino v spodnjem delu hrbta in nogah);
What Cyltezo is and what it is used for Cyltezo contains the active substance adalimumab, a medicine that acts on your body's immune (defence) 
Kaj je zdravilo Cyltezo in za kaj ga uporabljamo Zdravilo Cyltezo vsebuje učinkovino adalimumab, učinkovino, ki deluje na imunski (obrambni)
Consequently, Cyltezo can be used during breastfeeding. 
Posledično se zdravilo Cyltezo lahko uporablja med dojenjem.
Adalimumab was studied in 9,506 patients in pivotal controlled and open-label trials for up to 60 months or more. 
Adalimumab so raziskali pri 9.506 bolnikih v ključnih kontroliranih in odprtih preskušanjih, ki podpirajo vlogo za pridobitev dovoljenja za promet in so trajala do 60 mesecev ali več.
• nerve disorders (such as inflammation of the optic nerve to the eye and Guillain-Barré syndrome, a condition that may cause muscle weakness, abnormal sensations, tingling in the arms and upper body); 
• bolezni živčevja (kot je vnetje vidnega živca v očesu in sindrom Guillain-Barré, stanje, ki lahko povzroči šibkost mišic, nenormalna občutenja, mravljinčenje v rokah in zgornjem delu telesa);
Adalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells. 
Adalimumab je rekombinantno humano monoklonsko protitelo, pridobljeno v celicah jajčnika
Adalimumab demonstrated a treatment benefit in nail psoriasis patients with different extents of skin involvement (BSA ≥ 10% (60 % of patients) and BSA < 10 % and ≥ 5 % (40 % of patients)). 
Adalimumab je pokazal terapevtsko korist pri bolnikih s psoriazo nohtov z različnim obsegom prizadetosti kože (telesna površina ≥ 10 % (60 % bolnikov) in telesna površina < 10 % in ≥ 5 % (40 % bolnikov)).
Similar trends (not all statistically significant) were seen in the smaller randomised, double-blind, placebo-controlled AS study II of 82 adult patients with active ankylosing spondylitis. 
Podobni trendi (ki pa niso bili vsi statistično značilni) so bili opazni v manjši, randomizirani, dvojno slepi, s placebom kontrolirani študiji pri ankilozirajočem spondilitisu II pri 82 odraslih bolnikih z
In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 response from baseline at week 16 (see Tables 17 and 18). 
V študijah pri psoriazi I in II je bil primarni opazovani dogodek delež bolnikov, ki so od izhodišča do 16. tedna dosegli PASI 75 (glejte preglednici 17 in 18).
By attaching to TNFα, Cyltezo decreases the process of inflammation in these diseases. 
Zdravilo Cyltezo z vezavo na TNFα zmanjša vnetni proces pri teh boleznih.
Some of those patients were also treated with the medicines azathioprine or mercaptopurine. 
Nekateri od teh bolnikov so bili zdravljeni tudi z učinkovinama azatioprin ali merkaptopurin.
Cyltezo is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17 years and enthesitis-related arthritis in children and adolescents aged 6 to 17 years. 
Zdravilo Cyltezo se uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa pri otrocih in mladostnikih, starih 2 do 17 let in artritisa, povezanega z entezitisom pri otrocih in mladostnikih starih od 6 do 17 let.
The Cyltezo pre-filled pen is available in packs containing 1, 2, 4 and 6 pre-filled pens. 
Napolnjeni injekcijski peresnik z zdravilom Cyltezo je na voljo v pakiranjih po 1, 2, 4 in 6 napolnjenih injekcijskih peresnikov.
• If you have allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling or rash do not inject more Cyltezo and contact your doctor immediately since, in rare cases, these reactions 
• Če se pojavijo alergijske reakcije s simptomi, kot so tiščanje v prsih, piskajoče dihanje, omotica, otekanje ali izpuščaj, zdravila Cyltezo ne injicirajte več in se takoj posvetujte z zdravnikom, saj so v redkih primerih te reakcije lahko življenje ogrožajoče.
• hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal); 
• jetrnovranični T-celični limfom (redka oblika krvnega raka, ki je pogosto smrtna);
A modified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e. not identical to the TSS used for rheumatoid 
Za oceno so uporabili modificirani celotni seštevek po Sharpu (mTSS, modified Total Sharp Score), ki je vključil distalne interfalangealne sklepe (tj. ni bil enak TSS, ki se uporablja za revmatoidni artritis).
The symptoms described above can be signs of the below listed side effects, which have been observed with 
Opisani simptomi so lahko znaki naslednjih neželenih učinkov, ugotovljenih med uporabo
If your doctor determines that methotrexate is inappropriate, Cyltezo can be given alone. 
Če vaš zdravnik ugotovi, da metotreksat ni primeren, lahko zdravilo Cyltezo dobivate samo.
In post-marketing experience from January 2003 to December 2010, predominantly in patients with rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment years. 
V obdobju trženja od januarja 2003 do decembra 2010 je bil pretežno pri bolnikih z revmatoidnim artritisom zabeleženi delež malignomov približno 2,7 na 1.000 bolnikov-let zdravljenja.
Significant improvements at week 16 from baseline compared to placebo (Studies I and II) and MTX (Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). 
Značilno izboljšanje od izhodišča do 16. tedna se je v primerjavi s placebom (študiji I in II) in metotreksatom (študija II) izkazalo v dermatološkem indeksu kakovosti življenja (DLQI, Dermatology Life Quality Index).
In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality due to congestive heart failure have been observed. 
V kliničnem preskušanju z drugim antagonistom TNF so opažali poslabšanje kongestivnega srčnega popuščanja in večjo umrljivost zaradi kongestivnega srčnega popuščanja.
• Hold syringe at about a 45 degree angle to injection site, then insert needle into skin with a quick, 
• Iglo držite pod kotom približno 45 stopinj glede na mesto injiciranja, nato jo hitro vbodite v
What you need to know before you use Cyltezo 
Kaj morate vedeti, preden boste uporabili zdravilo Cyltezo